Abstract: The present invention relates to a method for reducing localized fat deposits in a subject in need thereof in need thereof by topically treating the subject with rare-earth element doped calcium carbonate particles in combination with low-intensity ultrasound. The rare-earth element doped calcium carbonate particles have good biocompatibility and can increase reactive oxygen species (ROS) production and produce carbon dioxide (CO2) and calcium ions (Ca2+) in the region of administration under the ultrasonic irradiation. The method of the present invention is effective in inducing adipocyte necrosis, inhibiting adipogenesis, and decreasing body weight and useful for body sculpture.

Abstract: An additive fabrication approach involves fabricating a platform on a build plate. The fabrication system is then calibrated based on the fabricated platform, and an object is then fabricating on the fabricated platform according to the calibration.

Abstract: A surgical instrument includes a rod and a push portion. The push portion includes a first end connected to an end of the rod and a second end having a blade portion. The push portion includes a plurality of grooves. The plurality of grooves is recessed in a surface of the push portion and is spaced from each other. Each two adjacent grooves has a rib formed therebetween. A top face of a cross section of each rib is the surface of the push portion. Each rib has a guiding face on the cross section of the push portion. The guiding face is connected to the surface of the push portion. The guiding face faces a rotating direction of the rod. An angle between the guiding face and the surface of the push portion in the cross section is greater than 90°.

Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein variables are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition, particularly Bcl-2 WT and/or Bcl-2 G101V.

Abstract: A support element assembly includes at least two types of standard blocks. The standard blocks are connected to each other and selected from the group consisting of a first standard block having a first elastic constant and a first height, a second standard block having a second elastic constant and the first height, a third standard block having the first elastic constant and a second height, and a fourth standard block having the second elastic constant and the second height. The standard blocks are manufactured by 3D printing and have identical lattices, and each standard block has a jointing structure.

Abstract: The present invention relates to compounds of e.g. formula (I) as BCL-2 inhibitors for the treatment of neoplastic, autoimmune or neurodegenerative diseases. Preferred compounds are e.g. fused 1H-pyrrolo[2,3-b]pyridine derivatives of e.g.

Abstract: Microfluidic device and application method thereof are provided. The microfluidic device includes a first substrate and a second substrate that are oppositely arranged along a first direction; and a first storage box and a second storage box that are oppositely arranged along the first direction. The first direction is a thickness direction of the microfluidic device. The first storage box includes a first storage cavity and a first opening communicating with the first storage cavity, and the first substrate is fixed in the first storage cavity. The second storage box includes a second storage cavity and a second opening communicating with the second storage cavity, and the second substrate is fixed in the second storage cavity. Along the first direction, the first opening is arranged opposite to the second opening and the first storage box is nested with the second storage box.

Abstract: The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cereblon (CRBN) ubiquitination inhibitors, as synthetic intermediates that can be used to prepare PROTAC molecules, or as PROTAC molecules. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing cancer and other diseases.

Abstract: An apparatus for monitoring sleep quality includes a plurality of sensors, a plurality of actuator modules, a transceiver, and a processor operatively coupled with the plurality of sensor modules, the plurality of actuator modules, and the transceiver. The processor is configured to monitor a sleep session of a user utilizing the apparatus. To monitor the sleep session, the processor is further configured to monitor a sleep state of the user, monitor a sleep stage of the user, and monitor a sleep condition. The processor is further configured to select a sleep facilitating action, control the sleep facilitating action based on the monitoring, and collect data related to the sleep session, and update a sleep history database associated with the user based on the data related to the sleep session.

Abstract: Disclosed are a dihydropyrimidine compound, a preparation method therefor and an application thereof. Specifically, disclosed are a dihydropyrimidine compound represented by formula 1? or a pharmaceutically acceptable salt thereof, a composition comprising the compound, and an application of the compound in preparing a drug for treating and preventing hepatitis B virus (HBV) infection related diseases. The disclosed dihydropyrimidine compound can effectively suppress the activity of HBV in HepG2.2.15 cells, and is less toxic to liver cancer cells.

Abstract: The invention relates to the field of medicinal chemistry, in particular to a substituted diaryl compound shown as a formula (I), a preparation method of the substituted diaryl compound, a medicinal preparation containing the substituted diaryl compound and medical application of the substituted diaryl compound. Pharmacological test results show that the substituted diaryl compound disclosed by the invention has a good inhibition effect on cells of human lung cancer (A549), human ovarian cancer (SKOV3), human melanoma (A375) and human colon cancer (LOVO).

Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.

Abstract: Substituted pyridazine phenol derivatives and a preparation method therefor, specifically relating to a compound as shown in formula (VI) and a pharmaceutically acceptable salt thereof, which can be used as an NLRP3 inhibitor.

Abstract: Provided are compounds comprising a six-membered aromatic ring which is fused to two either 5- or 6-membered rings, from which at least one ring is non-aromatic. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) as well as related consumer products that utilize these compounds.

Abstract: A steel alloy with unique and superior combinations of properties such as elevated temperature strength, oxidation resistance, thermal conductivity and wear resistance. Disclosed embodiments comprise or substantially consist of: C in an amount of 0.2-0.45 weight %; Si in an amount of 0.6-1.1 weight %; Mn in an amount of ?1.1 weight %; Cr in an amount of 2.5-4.0 weight %; one or both of Mo or W, a combined amount of the Mo or W?0.9 weight %; Ti in an amount of 0.035-0.14 weight %; V in an amount of 0.18-1.1 weight % and the balance being Fe and usual impurities.

Abstract: The present application provides a method for promoting the sternness and/or transdifferentiation of acinar cells, comprising the following steps: providing an acinar cell, transfecting a plasmid into the acinar cell, and culturing the transfected acinar cell, wherein the plasmid contains a genetic material for overexpression of N-acetylglucosaminyltransferase V (GnT-V).

Abstract: An anti-diffusion substrate structure includes a substrate, a substrate circuit layer, and a chip. The substrate has multiple through holes. Within each of the through holes includes a first metal layer and an anti-diffusion layer plated on the first metal layer. The anti-diffusion layer is an Electroless Palladium Immersion Gold (EPIG) layer or an Electroless Nickel Electroless Palladium Immersion Gold (ENEPIG) layer. The substrate circuit layer is mounted on the substrate and extended on the anti-diffusion layer within each of the through holes. The substrate circuit layer is made of a second metal layer, and a composition of the second metal layer is different from a composition of the first metal layer. The chip is electrically connected to the substrate circuit layer. The anti-diffusion layer is able to better prevent material of the first metal layer from migrating or diffusing to the second metal layer.

Abstract: A high-nickel ternary core-shell precursor for a lithium battery, a positive electrode material and a preparation method therefor. The chemical structural formula of the precursor is zNi(C4H7N2O2)2—Nix-zM1yM21-x-y(OH)2, wherein M1 and M2 are two of cobalt, aluminum, and manganese. The preparation method comprises: pumping a prepared metal salt solution, a dimethylglyoxime-ammonia water composite solution, and an ammonia water solution into a reaction kettle, maintaining the pH of a reaction system, and controlling the reaction time to obtain a sphere-like precursor inner core with a structural formula of Ni(C4H7N2O2)2; pumping the metal salt solution and the ammonia water solution, stopping pumping the dimethylglyoxime-ammonia water composite solution, pumping a sodium hydroxide solution to obtain a sphere-like core-shell precursor, washing, drying, sieving and deironing the precursor, mixing with a lithium source, and calcining to prepare the positive electrode material.

Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Abstract: A media playing method-includes: receiving a first play request of an application, where the first play request includes a first identifier; sending a first address to the application, where the first address is a local uniform resource locator URL address; buffering, from a server device to a client device, a target media resource that is in the server and that corresponds to the first identifier; and sending, when receiving a second play request sent by the application program to the first address, the buffered target media resource to the application program for playing.